Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.70 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.70 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.37 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084525 | 1.00 | KDM1A (0.70) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL22677681 | 1.00 | KDM1A (0.70) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL24270410 | 1.00 | KDM1A (0.70) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL24270420 | 1.00 | KDM1A (0.70) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL24270417 | 0.97 | KDM1A (0.69) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL24270411 | 0.96 | KDM1A (0.74) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL22677632 | 0.96 | KDM1A (0.74) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL22678308 | 0.96 | KDM1A (0.74) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL22678305 | 0.96 | KDM1A (0.74) | KDM1ARCOR1TERF2IDEPSMB5 | |
| SCHEMBL24270449 | 0.96 | KDM1A (0.74) | KDM1ARCOR1TERF2IDEPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4496567-A1 | USES OF BLETILLA FORMOSANA EXTRACT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION OF NEUTROPHILS | Chang Gung University (TW) | 2025-01-29 | — | — | EP | claimed |
| US-20240269220-A1 | USES OF BLETILLA FORMOSANA EXTRACT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION OF NEUTROPHILS | CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2024-08-15 | — | — | US | claimed |
| WO-2023178592-A1 | USES OF BLETILLA FORMOSANA EXTRACT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION OF NEUTROPHILS | CHANG GUNG UNIVERSITY (CN) | 2023-09-28 | — | — | WO | claimed |
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | claimed |
| US-20260028552-A1 | Cationic Surfactants with Improved pH Stability and Their Use | LOCUS SOLUTIONS IPCO LLC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4673426-A1 | FUNCTIONALIZED BIODEGRADABLE SURFACTANTS AND METHODS USE | Locus Solutions IPCO, LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4565709-A1 | CATIONIC SURFACTANTS WITH IMPROVED PH STABILITY AND THEIR USE | Locus Solutions IPCO, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-114874293-B | Cyclic polypeptide compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2025-05-23 | — | — | CN | disclosed |
| EP-4554953-A1 | MODIFIED SOPHOROLIPIDS WITH ENHANCED DEFOAMING PROPERTIES | Locus Solutions IPCO, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250154189-A1 | Modified Sophorolipids with Enhanced Defoaming Properties | LOCUS SOLUTIONS IPCO, LLC | 2025-05-15 | — | — | US | disclosed |
| WO-2025074281-A1 | OLEFINIC QUATERNARY AMMONIUM COMPOUNDS | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-04-10 | — | — | WO | disclosed |
| CN-119655230-A | Method for improving secretion of antibacterial peptide by silkworms and application thereof | 江苏科技大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-117157411-A | Enhanced sophorolipid derivative | 轨迹方案IPCO有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023178592-A1 | USES OF BLETILLA FORMOSANA EXTRACT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION OF NEUTROPHILS | CHANG GUNG UNIVERSITY (CN) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178592-A1 | USES OF BLETILLA FORMOSANA EXTRACT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION OF NEUTROPHILS | CHANG GUNG UNIVERSITY (CN) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023172606-A1 | IMPROVED FOAMING BIOSURFACTANTS | LOCUS SOLUTIONS IPCO, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4136210-A1 | BACILLUS STRAIN FOR APPLICATIONS IN AGRICULTURE, LIVESTOCK HEALTH AND ENVIRONMENTAL PROTECTION | Locus IP Company, LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | disclosed |
| US-20230029570-A1 | Bacillus Strain for Applications in Agriculture, Livestock Health and Environmental Protection | LOCUS AGRICULTURAL SOLUTIONS, LLC | 2023-02-02 | — | — | US | disclosed |
| WO-2022174190-A1 | ENHANCED SOPHOROLIPID DERIVATIVES | LOCUS IP COMPANY, LLC (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028552-A1 | Cationic Surfactants with Improved pH Stability and Their Use | CTSD, SURF4, CFD | KDM1A 1214/4885RCOR1 4713/4885TERF2 4116/4885 |
| US-20250154189-A1 | Modified Sophorolipids with Enhanced Defoaming Properties | LIPA, MGLL, LPL | KDM1A 699/4885RCOR1 1484/4885TERF2 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.